Pulse Biosciences (NASDAQ:PLSE) Given New $74.00 Price Target at Canaccord Genuity Group

Pulse Biosciences (NASDAQ:PLSE) had its target price upped by Canaccord Genuity Group from $58.00 to $74.00 in a report issued on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. BTIG Research assumed coverage on shares of Pulse Biosciences in a report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price target on the stock. Needham & Company LLC boosted their price objective on shares of Pulse Biosciences from $58.00 to $64.00 and gave the company a “buy” rating in a research report on Friday. Mizuho set a $65.00 price objective on shares of Pulse Biosciences in a research note on Friday. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.60.

Pulse Biosciences Stock Up 0.4%

Shares of Pulse Biosciences stock traded up $0.22 during trading on Friday, reaching $53.29. The company’s stock had a trading volume of 428,197 shares, compared to its average volume of 373,557. The firm’s 50-day moving average is $51.55 and its two-hundred day moving average is $32.28. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $58.90. The company has a market cap of $3.77 billion, a price-to-earnings ratio of -44.04 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.52 million. During the same period last year, the company posted ($0.29) EPS. The business’s revenue for the quarter was down 54.1% compared to the same quarter last year. On average, equities research analysts anticipate that Pulse Biosciences will post -1.34 EPS for the current year.

Insider Transactions at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,036 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was purchased at an average price of $48.23 per share, with a total value of $49,966.28. Following the transaction, the chief operating officer owned 1,036 shares of the company’s stock, valued at approximately $49,966.28. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have bought 4,095 shares of company stock valued at $199,931 over the last ninety days. 74.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. Sterling Capital Management LLC grew its holdings in Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock worth $31,000 after purchasing an additional 549 shares during the period. Bender Robert & Associates purchased a new position in shares of Pulse Biosciences during the third quarter valued at approximately $379,000. Axxcess Wealth Management LLC bought a new stake in shares of Pulse Biosciences in the 3rd quarter worth approximately $242,000. Formula Growth Ltd. bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $832,000. Finally, Panoramic Capital LLC bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $2,719,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.